Research programme: invariant natural killer T cell receptor agonists - Portage Biotech
Alternative Names: iNKT therapeutics - Portage BiotechLatest Information Update: 28 Sep 2023
At a glance
- Originator Ludwig Institute for Cancer Research; University of Oxford
- Developer Portage Biotech
- Class Immunotherapies; Lipids; Small molecules
- Mechanism of Action Natural killer cell receptor agonists; Natural killer T cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Solid-tumours in United Kingdom (Parenteral)
- 01 Aug 2022 Portage Biotech enters into collaboration agreement with Stanford University for PORT-2 with iNKT cell therapies before August 2022
- 01 Aug 2022 Portage Biotech enters into collaboration agreement with University of Birmingham for PORT-2 with iNKT cell therapies before August 2022